Identifying Cut-off Values, Effects of AD Co-pathology, Sex Differences, and Temporal Changes of 123I-FP-CIT SPECT in Autopsy-proven LBD
Objective: We analyzed autopsy-proven Lewy body disease (LBD) and/or Alzheimer’s disease (AD) dementia patients with 123I-FP-CIT SPECT to investigate previously unclarified detailed aspects of 123I-FP-CIT…Seed amplification assay detects alpha-synuclein in cerebrospinal fluid in pre- and symptomatic autosomal dominant Alzheimer’s disease
Objective: To examine the ability to detect concurrent Lewy Body Disease via Lew Body pathology (LBP) in Autosomal Dominant Alzheimer’s Disease (ADAD) through detection of…Efficacy of Stimulant Use for Cognitive Fluctuations in Lewy Body Dementia: A Case Study
Objective: To evaluate the effectiveness of stimulants in reducing cognitive fluctuations in Lewy Body Dementia (LBD). Background: Lewy Body Dementia (LBD) is the 2nd most…Sex differences in regional densities of Lewy body pathology
Objective: To assess sex differences in regional Lewy body pathology densities and their clinical correlations in cases with Lewy body (LB) pathology at autopsy. Background:…Lewy Pathology in the Peripheral Nervous System of SNCA Duplication
Objective: This study aimed to investigate the degree, distribution, and biochemical profile of phosphorylated α-synuclein (p-α-syn) in the peripheral nervous system of patients with SNCA…Patient-derived α-synuclein seed amplification as a tool for evaluating small molecule aggregation inhibitors for Parkinson’s disease and Lewy Body Dementia therapeutics
Objective: To validate on-target engagement of disease-relevant ⍺-synuclein (a-syn) aggregates by WTX-607, WaveBreak’s small-molecule clinical candidate for Parkinson’s disease (PD) and Lewy body dementia (LBD),…Sex Differences for Regional Lewy Body Pathology in Pathologically-Defined Lewy Body Dementia
Objective: To investigate sex differences for regional Lewy body (LB) pathology burden, and regional LB pathology association with clinical diagnosis across people with a high…Cardiovascular Associations of Cortical Lewy Bodies in the Oldest Old: The 90+ study
Objective: To identify potential risk factors for cortical Lewy Bodies (CLB) in the oldest-old (> 90 years old), we investigated if cardiovascular medical histories, medication…Assessing the Accuracy of Clinical Diagnostic Criteria of Lewy Body Dementia for Detection of Lewy Body Disease in the Oldest-Old: The 90+ Study
Objective: To examine if Lewy Body dementia (LBD) clinical diagnostic criteria will be less accurate for detecting Lewy Body Disease (the pathological diagnosis) in the oldest-old…Accuracy of Clinical features for Substantia Nigra Hypopigmentation and Cortical Lewy Body Presence in the Oldest-Old: The 90+ Study
Objective: To improve clinical diagnostic accuracy of Lewy Body Dementia (LBD), we assessed if frontal release signs are a useful screening tool for cortical Lewy…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 10
- Next Page »